Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
DOI:
https://doi.org/10.53778/pjkd40353Ключевые слова:
Rejection, kidney transplant, acute rejection, chronic rejection, antibody mediated rejection, complement,, plasmapheresis, Bortezomib,, Rituximab, Eculizumab, TocilizumabАннотация
Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.
Загрузки
Опубликован
2021-01-31
Выпуск
Раздел
Review Article
Лицензия
Copyright (c) 2021 Salman Tahir Shafi
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 4.0 Всемирная.
Как цитировать
Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353
